EMA Recommends Extending Indications for Pembrolizumab and Adopted a New Pharmaceutical Form Along with a New Route of Administration By Ogkologos - October 3, 2025 273 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns treatment of patients with resectable locally advanced head and neck squamous cell carcinoma Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Adding Autologous Stem-Cell Transplantation to Triplet Treatment, Followed by Lenalidomide Maintenance... July 27, 2022 Study Shows Experimental Screening Test Can Detect Endometrial and Ovarian Cancers May 2, 2018 FDA Approves Daratumumab plus Hyaluronidase-fihj, Carfilzomib, and Dexamethasone for Relapsed or... December 2, 2021 Partnering with Small Business to Advance Innovation in Cancer Research and... February 21, 2019 Load more HOT NEWS Promising Signal of Efficacy for Adjuvant Nivolumab in Patients with Completely... Sacituzumab Govitecan Does Not Demonstrate a Statistically Significant OS Improvement in... Nivolumab Plus AVD Prolongs PFS in Adolescents and Adults with Advanced-Stage... EMA Recommends Extension of Indications for Ibrutinib
